Successfully raised approximately US$50 million through the private placement of series A preferred shares of China Ophthalmology Focus Limited in May 2019
Formation of Lee’s Pharmaceutical Taiwan Limited, registered and operated in Taiwan
Official launch of Sancuso® in China
Official launch of Rasilez® in China
Official launch of VSL#3® in China
Honoured with “Most Innovative Small and Medium-sized Pharmaceutical Enterprises Award in the Asia Pacific Region 2019” by Clarivate Analytics
Honoured with “Most Growing Award” at “China Enterprise Excellence Awards Ceremony 2019”
Honoured with “2019 China 2nd Future Unicorn Competition Top 10 in China”
2018
Completed the merger of CVie Therapeutics Limited with Windtree Therapeutics, Inc. in December 2018
Honoured with “The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area”
Honoured with “World Outstanding Chinese Award – Dr. Benjamin Li” by World Chinese Business Investment Foundation
2017
Official launch of Mictonorm® in China
Establishment of China Ophthalmology Focus Limited
Completed the acquisition of majority of shares in Windtree Therapeutics, Inc. at a consideration of US$10 million in November 2017
Successfully carried out the reorganization of CVie Therapeutics Company Limited into two companies: CVie Therapeutics Limited for Taiwan business and CVie Therapeutics Company Limited for China business
Successfully raised approximately US$7.5 million through the private placement of series A preferred shares of CVie Therapeutics Limited in May 2017
Honoured with “Best Listed Companies Category 2017” by Forbes
2015
Successfully raised approximately HK$383 million through the placement of new shares of the Company in April 2015
Formation of Lee’s Healthcare Industry Fund L.P. with a maximum fund size of US$20.2 million in August 2015
Inclusion to MSCI China Indexes
Inclusion to various Hang Seng Family of Indexes
Formation of Zhaoke Pharmaceutical (Guangzhou) Company Limited, registered and operated in Nansha District, Guangzhou, China
Establishment of Guangzhou Zhaokang Hospital Company Limited and acquisition of the land parcel with a total site area of approximately 36,656 m2 and with a total planned gross floor area of approximately 65,981m2 specifically for medical and sanitary use in Nansha District, Guangzhou, China in September 2015
Honoured with “Asia’s 200 Best Under a Billion” 2015 by Forbes
Honoured with “EY Entrepreneur of The Year 2015 China” by EY
2014
Official launch of Remodulin® in China
Formation of China Oncology Focus Limited with the management of the Company
2013
Official launch of Oral L-Carnitine® in China
Successfully raised approximately US$3 million through the private placement of series A-2 preferred shares of CVie Therapeutics Company Limited in March 2013
Successfully raised approximately US$10 million through the private placement of series B preferred shares of CVie Therapeutics Company Limited in August 2013
Honoured with “Asia’s 200 Best Under a Billion” 2013 by Forbes
2012
Official launch of Zanidip® in China
Successfully raised approximately HK$152 million through the placement of new shares of the Company to GL Trade Investment Limited in May 2012
Establishment of China Cardiovascular Focus Limited and CVie Therapeutics Company Limited
Successfully raised approximately US$4 million through the private placement of series A-1 preferred shares of CVie Therapeutics Company Limited in July 2012
Honoured with“Technology Achievement Award 2012” by Hong Kong Awards for Industries
Honoured with “Asia’s 200 Best Under a Billion” 2012 by Forbes
2011
Establishment of Guangzhou Zhaoke Lianfa Pharmaceutical Limited
Honoured with “Asia’s 200 Best Under a Billion” 2011 by Forbes
Honoured with “500 Best in Asia Pacific 2011” by Deloitte
2010
Successfully raised approximately HK$40 million through the placement of new shares of the Company to an investor in October 2010
Successfully transfer of listing from GEM to Main Board of the Stock Exchange of Hong Kong Limited (Stock code: 950) on 14 May 2010
Establishment of Powder Pharmaceuticals, Incorporated
Honoured with “500 Best in Asia Pacific 2010” by Deloitte
Honoured with “Hong Kong Outstanding Enterprises 2010” by Economic Digest
2009
Successfully raised approximately HK$19 million through the placement of new shares of the Company to an investor in August 2009
2008
Official launch of Eyprotor® in China
2006
Official launch of Slounase® in China
2005
Completed the acquisition of the interests in Zhaoke Pharmaceutical (Hefei) Company Limited from the PRC partner and became a wholly owned subsidiary of the Group
2004
Successfully raised approximately HK$24 million through the placement of new shares and unlisted warrants of the Company to an investor in August 2004
2003
Official launch of Carnitene® in China
2002
Lee’s Pharmaceutical Holdings Limited announced listing of Initial Public Offering of shares on the Growth Enterprise Market (“GEM”) of the Stock Exchange of Hong Kong Limited and the shares commenced trading on 15 July 2002
2001
Official launch of Yallaferon® in China
1998
Official launch of Livaracine® in China
1997
Official launch of Delibrase® in China
1994
Establishment of the Group
Formation of Zhaoke Pharmaceutical (Hefei) Company Limited with a PRC partner, registered and operated in Hefei City, Anhui Province, China
